1
|
Li P, Zhang K, Tang S, Tang W. Knockdown of lncRNA HAGLROS inhibits metastasis and promotes apoptosis in nephroblastoma cells by inhibition of autophagy. Bioengineered 2022; 13:7552-7562. [PMID: 35358010 PMCID: PMC9208483 DOI: 10.1080/21655979.2021.2023984] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 12/24/2021] [Accepted: 12/25/2021] [Indexed: 02/05/2023] Open
Abstract
Nephroblastoma, or Wilms tumor, is a primary renal malignant tumor that easily occurs in children. Previous studies have revealed the regulatory functions of LncRNA in nephroblastoma. LncRNA HAGLROS functions as a tumor promotor in various cancers including hepatocellular carcinoma, ovarian cancer and colorectal cancer. In this study, the HAGLROS expression in nephroblastoma cells was assayed through qRT-PCR. Cell proliferation assessment employed CCK-8. Moreover, the migration and invasion of cells were examined separately through wound healing and transwell assay. Moreover, flow cytometric analysis and Western blot assay were applied to evaluate cell apoptosis. Rapamycin and 3-methyladenine were used to serve as autophagy activator or inhibitor, respectively. In addition, autophagy was identified by immunofluorescence staining and Western blot analysis. Experiment results showed that HAGLROS expressed highly in nephroblastoma cell lines. HAGLROS knockdown prevented cells from proliferating, and also showed suppressive impact on migration and invasion in HFWT cells. In addition, knockdown of HAGLROS showed a facilitative effect on apoptosis and an inhibitory effect on autophagy. Stimulation of autophagy alleviated HAGLROS silencing-induced apoptosis, while inhibition of autophagy reversed the effect in nephroblastoma cells. In summary, our results revealed that HAGLROS executed an oncogenic role in the progress of nephroblastoma, offering a new perspective on the strategy for nephroblastoma therapy.
Collapse
Affiliation(s)
- Pugui Li
- Department of General Surgery, Taikang Xianlin Drum Tower Hospital, Nanjing, China
| | - Kun Zhang
- Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, China
| | - Shijie Tang
- Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, China
| | - Weizhu Tang
- Department of Urology, Nanping First Hospital, Nanping, China
| |
Collapse
|
2
|
Yang H, Wang C, Liao H, Wang Q. Activation of GPER by E2 promotes proliferation, invasion and migration of breast cancer cells by regulating the miR-124/CD151 pathway. Oncol Lett 2021; 21:432. [PMID: 33868470 PMCID: PMC8045164 DOI: 10.3892/ol.2021.12693] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 01/05/2021] [Indexed: 12/21/2022] Open
Abstract
Breast cancer is one of the most common malignancies worldwide and is responsible for a high mortality rate. However, the underlying pathological mechanism of breast cancer remains unclear. MicroRNAs (miRNAs/miRs) play critical roles in the progression of breast cancer. Recent studies have reported that miR-124/CD151 participates in the development of breast cancer. However, the exact molecular mechanism of miR-124/CD151 action in 17β-estradiol (E2)-treated breast cancer cells remains unknown. Thus, the present study aimed to investigate miR-124 and CD151 expression levels in MCF-7 cells treated with E2 via reverse transcription-quantitative PCR and western blot analyses. Bioinformatic analysis was performed to predict and identify whether CD151 is a potential target of miR-124. The Cell Counting Kit-8 and colony formation assays were performed to detect proliferation of MCF-7 cells. In addition, the invasive and migratory abilities of MCF-7 cells were assessed via the Transwell and wound healing assays, respectively. The results demonstrated that E2 downregulated miR-124 expression, while upregulating G protein -coupled estrogen receptor (GPER) expression in MCF-7 cells. Following treatment with the GPER antagonist, G15, miR-124 expression was significantly enhanced and E2-induced proliferation, invasion and migration of MCF-7 cells were notably inhibited. In addition, CD151 was confirmed as a direct target of miR-124. CD151 silencing remarkably suppressed the proliferation, invasion and migration of E2-induced MCF-7 cells. Taken together, these results suggest that upregulation of GPER expression induced by E2 promotes proliferation, invasion and migration of breast cancer cells by regulating the miR-124/CD151 pathway. Thus, the results of the present study provide a potential novel method for the treatment and prognosis of breast cancer.
Collapse
Affiliation(s)
- Huaicheng Yang
- Department of General Surgery, The Frist Affiliated Hospital of Anhui University of Science and Technology, Huainan, Anhui 232007, P.R. China
| | - Congyu Wang
- Department of General Surgery, The Frist Affiliated Hospital of Anhui University of Science and Technology, Huainan, Anhui 232007, P.R. China
| | - Heqiang Liao
- Department of General Surgery, The Frist Affiliated Hospital of Anhui University of Science and Technology, Huainan, Anhui 232007, P.R. China
| | - Qi Wang
- Department of General Surgery, The Frist Affiliated Hospital of Anhui University of Science and Technology, Huainan, Anhui 232007, P.R. China
| |
Collapse
|
3
|
Jiang L, Wang H, Zhu X, Liu W, Zhou S, Geng Z, Xiao Y, Zou P, You Y, Li Q, Zhu X. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation. Stem Cells Dev 2019; 28:1480-1485. [PMID: 31530245 DOI: 10.1089/scd.2019.0117] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
BCR-ABL1 tyrosine kinase inhibitors (TKIs) are selective therapies for patients with chronic myeloid leukemia (CML) and induce deep molecular response (DMR). However, ∼60% of patients relapse after the discontinuation of TKIs. Relapse after discontinuation is likely due the inability of TKIs to eradicate CML stem cells (CML-LSCs). In our previous study, 12 out of 22 patients maintained a stable DMR after TKI withdrawal, and we found that fewer patients who were treated with second-generation TKI relapsed compared with those receiving imatinib. Therefore, we hypothesized that second-generation TKIs and imatinib may have different effects on CML-LSCs, which may affect the clinical outcome after TKI discontinuation. To investigate this, we established a TKI discontinuation model in vitro by treating CML CD34+ cells with imatinib and dasatinib continuously for 72 h and then removing the TKI for 24 h. Colony-forming cell (CFC) assays, apoptosis assessment, and proteomic analysis were then performed. We found that TKI discontinuation resulted in less proliferation and CFC output in dasatinib-treated cells compared with imatinib. However, the dasatinib-treated group exhibited increased apoptosis. In the proteomics analysis, we identified 160 upregulated and 151 downregulated proteins when the two TKI discontinuation groups were compared. Importantly, proteins involved in NAD+ nucleosidase activity, mitochondrial ATP synthesis coupled proton transport, and oxidative phosphorylation were significantly expressed, which were mainly involved in metabolic processes. In conclusion, we demonstrate that imatinib and dasatinib have clear differential effects on CML-LSCs through the regulation of mitochondria oxidative phosphorylation, which may provide a new target for eliminating CML-LSCs in the context of TKI discontinuation.
Collapse
Affiliation(s)
- Lin Jiang
- Department of Hematology, the Central Hospital of Wuhan, Wuhan, China
| | - Hongxiang Wang
- Department of Hematology, the Central Hospital of Wuhan, Wuhan, China
| | - Xiaoying Zhu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Wen Liu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Shu Zhou
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zhe Geng
- Department of Hematology, the Central Hospital of Wuhan, Wuhan, China
| | - Yi Xiao
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Ping Zou
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yong You
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qing Li
- Department of Hematology, Wuhan No.1 Hospital, Wuhan, China
| | - Xiaojian Zhu
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
4
|
Tan R, Cheng H, Li H, Tu Y. Clinical Chemistry Route for Investigation of Alzheimer's Disease: A Label-Free Electrochemiluminescent Biosensor for Glycogen Synthase Kinase-3 Beta. ACS Chem Neurosci 2019; 10:3758-3768. [PMID: 31322849 DOI: 10.1021/acschemneuro.9b00278] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Herein, we report a novel label-free electrochemiluminescent (ECL) biosensor for the detection of glycogen synthase kinase-3 beta (GSK-3β). A simple and feasible sensor was prepared by a two-step process. A polymeric coordination layer of phosphorylated poly vinyl with Zr4+ was used as the sensory hosting matrix because it efficiently formed a complex. The exterior Zr4+ can further combine with another phosphate through coordination, and GSK-3β catalyzes the phosphorylation of protein molecules. Thus, the biosensor can detect GSK-3β using luminol as an ECL probe. The ECL intensity of the proposed sensor responded proportionally to the concentration of GSK-3β under direct immersion mode with a linear response in a logarithmic scale over the wide range from 0.5 to 91.5 ng L-1 and a detection limit of 0.055 ng L-1. Excellent selectivity, stability, and reproducibility were achieved using the prepared biosensor, which has a simple preparation, low cost, and disposable suitability. This work aims to provide a novel tool for early diagnosis and pathological mechanism exploration about AD by detecting inchoate change of GSK-3β content in body fluid, thus to precaution the risk of Alzheimer's disease. It is of great importance for clinical chemistry for the investigation of Alzheimer's disease.
Collapse
Affiliation(s)
- Rong Tan
- College of Chemistry, Chemical Engineering and Materials, Soochow University, Suzhou, 215123, P. R. China
| | - Hongying Cheng
- School of Chemistry, Biology and Materials Engineering, Suzhou University of Science and Technology, Suzhou 215009, P. R. China
| | - Huiling Li
- College of Nursing, Soochow University, Suzhou, 215006, P. R. China
| | - Yifeng Tu
- College of Chemistry, Chemical Engineering and Materials, Soochow University, Suzhou, 215123, P. R. China
| |
Collapse
|